ArticleJournal of inflammation research2026
S100A8/A9 Inhibition Reduces Neutrophil Extracellular Trap Formation and Mitigates Sepsis-Related Liver Injury.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Sepsis is a leading cause of death in patients admitted to the intensive care unit. Sepsis-related liver injury (SRLI) is a fatal complication of sepsis with limited early diagnostic and therapeutic options. We investigated the role of the damage-associated molecular patterns S100A8/A9 in SRLI pathogenesis, with particular focus on their interaction with neutrophil extracellular traps (NETs). Patients and Methods: Bioinformatics analysis of sepsis datasets from the Gene Expression Omnibus database was integrated with clinical validation using an enzyme-linked immunosorbent assay with patient plasma. The functional role of S100A8/A9 was further explored in a murine cecal ligation and puncture (CLP) sepsis model. Mice were pretreated with the S100A8/A9 inhibitor paquinimod to assess its effects on NET formation (via immunofluorescence and Western blotting), liver injury (serum alanine aminotransferase and aspartate aminotransferase levels and histopathology), inflammatory response (cytokine levels), and survival rates. Results: Bioinformatics analysis identified S100A8/A9 as a key hub gene in sepsis. Clinically, plasma S100A8/A9 levels were significantly elevated in patients with sepsis, particularly in those with liver injury. In CLP mice, hepatic S100A8/A9 was upregulated, and paquinimod-induced inhibition of S100A8/A9 markedly reduced NET formation, lowered interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha levels, alleviated liver damage, and improved survival rates. Transcriptome sequencing revealed alterations in immune and metabolic pathways. Conclusion: This study suggests that elevated S100A8/A9 and concurrent NETosis are closely associated with sepsis-related liver injury (SRLI). S100A8/A9 can be used as a potential predictive biomarker for early liver dysfunction, and prophylactic administration of paquinimod can reduce intrahepatic inflammation, reduce NET formation, and improve the survival rate of mice with sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.